AAAAAA

   
Results: 1-14 |
Results: 14
CONFIRMATORY INTERLEUKIN-1 RECEPTOR ANTAGONIST TRIAL IN SEVERE SEPSIS- A PHASE-III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER TRIAL
Authors: OPAL SM FISHER CJ DHAINAUT JFA VINCENT JL BRASE R LOWRY SF SADOFF JC SLOTMAN GJ LEVY H BALK RA SHELLY MP PRIBBLE JP LABRECQUE JF LOOKABAUGH J DONOVAN H DUBIN H BAUGHMAN R NORMAN J DEMARIA E MATZEL K ABRAHAM E SENEFF M BARBER A BRAYMAN K CERRA F CHALFIN D CHAZEN G CHRISTOU N COONEY R CORBIN R DREW R EMMANUEL G PINES B ERON L FLETCHER R FOULKE G GALLAGHER T GERVICH D GROSSMAN J HALPERN N HANNA C JOHNSON S KUBAK B LODATO R LOVETT M MARSHALL J METZLER M NELSON L FREELAND M OROPELLO J PAZ H RACKOW E RIKER R RISSING P SCHEIN R SCHELD M SCHUSTER D SIBBALD W SILVERMAN H SOMERMEYER M STRANGE C SUMMER W TOPIEL M WHITE J ALESTIG K ANDERSEN PK ANDERSSON J BENNETT D BERG S BLEICHNER G BRUNET F CARLET J DEJONG MJ DREXLER H GARRARD C HESLET L KLOSS T PAUL W REINHART K RENAUD B RITZ R ROMME JH SCHMITZ JE STOCKENHUBER F SUTER P TENAILLON A VAGT A VANDERMEER WM VANDEVENTER S VANLEEUWEN PAM VERHOEF J WEBSTER N WINTER RJ WOLFF M STILES DM DEVOS A CROFT C FAZIO J THOMPSON R WIEDEMANN H ELLISON RT CHINCHILLI VM YARBOROUGH M
Citation: Sm. Opal et al., CONFIRMATORY INTERLEUKIN-1 RECEPTOR ANTAGONIST TRIAL IN SEVERE SEPSIS- A PHASE-III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER TRIAL, Critical care medicine, 25(7), 1997, pp. 1115-1124
ACUTE-RENAL-FAILURE IN INTENSIVE-CARE UNITS - CAUSES, OUTCOME, AND PROGNOSTIC FACTORS OF HOSPITAL MORTALITY - A PROSPECTIVE, MULTICENTER STUDY
Authors: BRIVET FG KLEINKNECHT DJ LOIRAT P LANDAIS PJM BEDOCK B BLEICHNER G RICHARD C COSTE F BRUNBUISSON C SICOT C TENAILLON A GAJDOS P BLIN F SAULNIER F AGOSTINI MM NICOLAS F FERYLEMONNIER E STAIKOWSKI F CARLET J GUIVARCH G FRAISSE F RICOME J TEMPE JD MEZZAROBBA P
Citation: Fg. Brivet et al., ACUTE-RENAL-FAILURE IN INTENSIVE-CARE UNITS - CAUSES, OUTCOME, AND PROGNOSTIC FACTORS OF HOSPITAL MORTALITY - A PROSPECTIVE, MULTICENTER STUDY, Critical care medicine, 24(2), 1996, pp. 192-198
USE OF PREDICTED RISK OF MORTALITY TO EVALUATE THE EFFICACY OF ANTICYTOKINE THERAPY IN SEPSIS
Authors: KNAUS WA HARRELL FE LABRECQUE JF WAGNER DP PRIBBLE JP DRAPER EA FISHER CJ SOLL L ASTIZ M RACKOW EC CARPATI C BALK RA FRIEDMAN B MURE AJ SHAPIRO E MELHOM L SHAPIRO MJ TAYLOR R KEEGAN M OBRIEN J GREENMAN RL SCHEIN R PENA M WASSERLOUF M IBERTI TJ OROPELLO J BENJAMIN E DELGUIDICE R EMMANUEL G LIE T ANDERSON L MARSHALL J DEMAJO W ROTSTEIN O FOSTER D ABRAHAM E MIDDLETON H PERRY C LEVY H FRY DE SIMPSON SQ CROWELL RE NEIDHART M STEVENS D COFFMAN T NARASIMHAN N MERRICK DK BERQUIST W MATZEL K HUEBLER M FOULKE G ALBERTSON T WALBY W ALLEN R BAUGHMAN R HASSELGREN PO FINK MP FAVORITO F THOMAS BT CORBIN R SHELLHORSE GY FRAZIER A WHITE S GARRARD C ACOURT C GERVICH D BRASE R BAGDAHN A COONEY R SMITH JS VINCENT JL FRIEDMAN G BERLOT G FLETCHER JR WILLIAMS MD WRIGHT TF JOHNSON S FEILD C WOLF K MACINTYRE N DUBIN H DURKIN M STAUBACH KH FEIN AM SCHULMAN DB NIEDERMAN MS CHALFIN DB VANLEEUVEN PAM BANDER J IMM A BERNARD G NELSON L STROUD M SAFCSAK K CERRA F RINDAL J MANN H HALPERN N ALICEA M SIBBALD WJ MARTIN CM RUTLEDGE FS PETTI K RUSSELL J KRUGER R DRUMMOND A FISHER CS LANGE P SELFERT T DUROCHER A TENAILLON A BOITEAU R LHERM T LOWRY S COYLE SM BARIE PS DEMARIA E REINES HD SNYDMAN D SCHWAITZBERG S NASRAWAY S GRINDLINGER J SUMMER W DEBOISBLANC B WAHL M ALESTIG K GROSSMAN J MAKI D PAZ HL WEINER M BIHARI D BLEICHNER G DAHN M HALL J WENZEL RP GROSSERODE M COSTIGAN M MILESKI W WEIGELT J YESTON N IRIZARRY C ROSS J ROBBINS J SHELLY MP NIGHTINGALE P OWEN K SANDSTEDT S BERG S SIMON G SENEFF M CONRY K ZIMMERMAN JL DELLINGER RP JOHNSTON R ALLEE P GRANDE PO MYHRE E DHAINAUT JF HAMY I MIRA JP HARMON J WHITE J MCKIE L SILVERMAN H TUMA P BENNETT D LAURELL MH JACOBS S ASH S OPAL SM SLOTMAN GJ IBERTI TJ SADOFF JC STILES DM THOMPSON B PRIOR MJ KNATTERUD G TERRIN M KUFERA J WILKENS P RA K MONROE L SPRUNG C HAMILTON CM MATTHAY R MCCABE W TONASCIA J WIEDMAN H WITTES J THOMPSON BW LABRECQUE JF CATALANO MA CAMPION GV CROFT CR LUSTICK R LOOKABAUGH J GORDON GS NOE L BLOEDOW D SMITH CG BRANNON D KUSH R NG D MOORE E BAZEMORE K GALVAN M WAGNER D HARRELL F STABLEIN D
Citation: Wa. Knaus et al., USE OF PREDICTED RISK OF MORTALITY TO EVALUATE THE EFFICACY OF ANTICYTOKINE THERAPY IN SEPSIS, Critical care medicine, 24(1), 1996, pp. 46-56
SEVERE COMMUNITY-ACQUIRED PNEUMOCOCCAL PNEUMONIA
Authors: MOINE P VERCKEN JB CHEVRET S GAJDOS P SCHLEMMER B GARROUSTE MT MUIR JF DEFOUILLOY C THALER F TENAILLON A CARLET J TIMSIT JF VERCKEN JB GAJDOS P DEROHANCHABOT P BOLES JM OUTIN H TEMPE JD SCHNEIDER F HOLZAPFEL L SOLLET JP PETITPRETZ P FRAISSE F GBIKPIBENISSIAN G CARDINAUD JP BRUNBUISSON C
Citation: P. Moine et al., SEVERE COMMUNITY-ACQUIRED PNEUMOCOCCAL PNEUMONIA, Scandinavian journal of infectious diseases, 27(3), 1995, pp. 201-206
NEBULIZED VERSUS INTRAVENOUS ALBUTEROL IN HYPERCAPNIC ACUTE ASTHMA - A MULTICENTER, DOUBLE-BLIND, RANDOMIZED STUDY
Authors: SALMERON S BROCHARD L MAL H TENAILLON A HENRYAMAR M RENON D DUROUX P SIMONNEAU G
Citation: S. Salmeron et al., NEBULIZED VERSUS INTRAVENOUS ALBUTEROL IN HYPERCAPNIC ACUTE ASTHMA - A MULTICENTER, DOUBLE-BLIND, RANDOMIZED STUDY, American journal of respiratory and critical care medicine, 149(6), 1994, pp. 1466-1470
RECOMBINANT HUMAN INTERLEUKIN-1 RECEPTOR ANTAGONIST IN THE TREATMENT OF PATIENTS WITH SEPSIS SYNDROME - RESULTS FROM A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL
Authors: FISHER CJ DHAINAUT JFA OPAL SM PRIBBLE JP BALK RA SLOTMAN GJ IBERTI TJ RACKOW EC SHAPIRO MJ GREENMAN RL REINES HD SHELLY MP THOMPSON BW LABRECQUE JF CATALANO MA KNAUS WA SADOFF JC ASTIZ M CARPATI C BONE RC FREIDMAN B MURE AJ BRATHWAITE C SHAPIRO E MELHORN L TAYLOR R KEEGAN M OBRIEN J SCHEIN R PENA M WASSERLOUF M OROPELLO J BENJAMIN E DELGUIDICE R EMMANUEL G LIE T ANDERSON L MARSHALL J DEMAJO W ROTSTEIN O FOSTER D ABRAHAM E MIDDLETON H PERRY C LEVY H FRY DE SIMPSON SQ CROWELL RE NEIDHART M STEVENS D COFFMAN T NARASIMHAM N MERRICK DK BERGQUIST W MATZEL KE HUEBLER M FOULKE GE ALBERTSON TE WALBY WF ALLEN RP BAUGHMAN R HASSELGREN PO FINK MP FAVORITO F THOMPSON BT CORBIN R SHELLHORSE GY FRAZIER A WHITE S GARRARD C ACOURT C STORER S GERVICH DH FOSHE D BRASE R BAGDAHN A COONEY R SMITH JS MARTIN LF VINCENT JL FRIEDMAN G BERLOT G FLETCHER JR WILLIAMS MD WRIGHT TF JOHNSON S FEILD C WOLF K MACINTYRE N DUBIN HG DURKIN MR DUBIN PK STAUBACH KH FEIN AM SCHULMAN DB NIEDERMAN MS CHALFIN DB VANLEEUWEN PAM BOERMEESTER MA SCHNEIDER AJ BANDER J IMM A BERNARD G NELSON L STROUD M SAFCSAK K CERRA F RINDAL J MANN H HALPERN N SILVERSTEIN J ALICEA M SIBBALD WJ MARTIN CM RUTLEDGE FS PETTI K RUSSELL JA KRUGER R DRUMMOND A LANGE P SEIFERT T DUROCHER A TENAILLON A BOITEAU R LHERM T LOWRY SF COYLE SM BARIE PS DEMARIA E SNYDMAN DR SCHWAITZBERG SD NASRAWAY SA GRINDLINGER J SUMMER W DEBOISBLANC B WAHL M ALESTIG K GROSSMAN J MAKI D PAZ HL WEINER M BIHARI D CAMPBELL D BLEICHNER G DAHN MS LANGE MPA HALL J POHLMAN A WENZEL RP GROSSERODE M COSTIGAN M MILESKI W WEIGELT J YESTON N IRIZARRY C ROSS J ROBBINS J NIGHTINGALE P OWEN K SANDSTEDT S BERG S SIMON GL SENEFF MG CONRY KM ZIMMERMAN JL DELLINGER RP JOHNSTON R ALLEE P GRANDE PO MYHRE E DHAINAUT JF HAMY I MIRA JP HARMON J WHITE J MCKIE L SILVERMAN H TUMA P BENNETT D PORTER JC LAURELL MH JACOBS S ASH S STILES DM PRIOR MJ KNATTERUD G TERRIN M KUFERA J WILKENS P RA K MONROE L SPRUNG C HAMILTON CM MATTHAY R MCCABE W TONASCIA J WIEDEMAN H WITTES J CAMPION GV CROFT CR LUSTICK R LOOKABAUGH J GORDON GS NOE L BLOEDOW D SMITH CG BRANNON D KUSH R NG D MOORE E BAZEMORE K GALVAN M WAGNER D HARRELL F STABLEIN D
Citation: Cj. Fisher et al., RECOMBINANT HUMAN INTERLEUKIN-1 RECEPTOR ANTAGONIST IN THE TREATMENT OF PATIENTS WITH SEPSIS SYNDROME - RESULTS FROM A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL, JAMA, the journal of the American Medical Association, 271(23), 1994, pp. 1836-1843
PLATELET-ACTIVATING-FACTOR RECEPTOR ANTAGONIST BN-52021 IN THE TREATMENT OF SEVERE SEPSIS - A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED,MULTICENTER CLINICAL-TRIAL
Authors: DHAINAUT JFA TENAILLON A LETULZO Y SCHLEMMER B SOLET JP WOLFF M HOLZAPFEL L ZENI F DREYFUSS D MIRA JP DEVATHAIRE F GUINOT P
Citation: Jfa. Dhainaut et al., PLATELET-ACTIVATING-FACTOR RECEPTOR ANTAGONIST BN-52021 IN THE TREATMENT OF SEVERE SEPSIS - A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED,MULTICENTER CLINICAL-TRIAL, Critical care medicine, 22(11), 1994, pp. 1720-1728
SEVERE COMMUNITY-ACQUIRED PNEUMONIA - ETIOLOGY, EPIDEMIOLOGY, AND PROGNOSIS FACTORS
Authors: MOINE P VERCKEN JB CHEVRET S CHASTANG C GAJDOS P SCHLEMMER B GARROUSTE MT MUIR JF DEFOUILLOY C THALER F TENAILLON A CARLET J TIMSIT JF DEROHANCHABOT P BOLES JM OUTIN H TEMPE JD SCHNEIDER F HOLZAPFEL L SOLLET JP PETITPRETZ P FRAISSE F GBIKPIBENISSIAN G CARDINAUD JP BRUNBUISSON C
Citation: P. Moine et al., SEVERE COMMUNITY-ACQUIRED PNEUMONIA - ETIOLOGY, EPIDEMIOLOGY, AND PROGNOSIS FACTORS, Chest, 105(5), 1994, pp. 1487-1495
EFFICACY OF PAF ANTAGONIST (BN-52021) IN REDUCING MORTALITY OF PATIENTS WITH SEVERE GRAM-NEGATIVE SEPSIS
Authors: TENAILLON A DHAINAUT JF LETULZO Y SCHLEMMER B SOLET JP WOLFF M HOLZAPFEL L ZENI F DREYFUSS D MIRA JP CHRETIEN JM LAVERGNE V GUINOT P
Citation: A. Tenaillon et al., EFFICACY OF PAF ANTAGONIST (BN-52021) IN REDUCING MORTALITY OF PATIENTS WITH SEVERE GRAM-NEGATIVE SEPSIS, The American review of respiratory disease, 147(4), 1993, pp. 97-97
EFFICACY OF PAF ANTAGONIST (BN-52021) IN REDUCING MORTALITY OF PATIENTS WITH SEVERE GRAM-NEGATIVE SEPSIS
Authors: TENAILLON A DHAINAUT JF LETULZO Y SCHLEMMER B SOLET JP WOLFF M HOLZAPFEL L ZENI F DREYFUSS D MIRA JP CHRETIEN JM LAVERGNE V GUINOT P
Citation: A. Tenaillon et al., EFFICACY OF PAF ANTAGONIST (BN-52021) IN REDUCING MORTALITY OF PATIENTS WITH SEVERE GRAM-NEGATIVE SEPSIS, The American review of respiratory disease, 147(4), 1993, pp. 196-196
PREVENTION OF NASAL ESCHARS IN PATIENTS WITH NASOGASTRIC TUBES (NGT) AND OR NASOPHARYNGEAL TUBES (NTP) BY AN HYDROCOLLOID WAFER (DUODERM(R))
Authors: BOITEAU R LHERM T COVELLI M LEROY C TENAILLON A PERRINGACHADOAT D
Citation: R. Boiteau et al., PREVENTION OF NASAL ESCHARS IN PATIENTS WITH NASOGASTRIC TUBES (NGT) AND OR NASOPHARYNGEAL TUBES (NTP) BY AN HYDROCOLLOID WAFER (DUODERM(R)), The American review of respiratory disease, 147(4), 1993, pp. 411-411
OROTRACHEAL (OTI) VS NASOTRACHEAL (NTI) INTUBATION - INFLUENCE ON PERFORMANCES OF HEAT AND MOISTURE EXCHANGERS (HME)
Authors: BOITEAU R LHERM T CHAMIEH F VALENTE E TENAILLON A PERRINGACHADOAT D
Citation: R. Boiteau et al., OROTRACHEAL (OTI) VS NASOTRACHEAL (NTI) INTUBATION - INFLUENCE ON PERFORMANCES OF HEAT AND MOISTURE EXCHANGERS (HME), The American review of respiratory disease, 147(4), 1993, pp. 889-889
INFLUENCE OF THE EXPIRATION CONTROL ON RESPIRATORY MECHANICS
Authors: BOITEAU R LHERM T TENAILLON A MASSON P
Citation: R. Boiteau et al., INFLUENCE OF THE EXPIRATION CONTROL ON RESPIRATORY MECHANICS, The American review of respiratory disease, 147(4), 1993, pp. 889-889
EFFECT OF A NEW VENTILATION MODE DECELERATED CONTROLLED EXPIRATION (DCE) ON GAS-EXCHANGE
Authors: BOITEAU R LHERM T TENAILLON A MASSON P
Citation: R. Boiteau et al., EFFECT OF A NEW VENTILATION MODE DECELERATED CONTROLLED EXPIRATION (DCE) ON GAS-EXCHANGE, The American review of respiratory disease, 147(4), 1993, pp. 889-889
Risultati: 1-14 |